Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleWorkshops and Special Sessions

Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop

Esi M. Morgan, Jane E. Munro, Jennifer Horonjeff, Ben Horgan, Beverley Shea, Brian M. Feldman, Hayyah Clairman, Clifton O. Bingham III, Susan Thornhill, Vibeke Strand, Alessandra Alongi, Silvia Magni-Manzoni, Marion A.J. van Rossum, Richard Vesely, Jelena Vojinovic, Hermine I. Brunner, Julia G. Harris, Daniel B. Horton, Daniel J. Lovell, Melissa Mannion, Homaira Rahimi, Angelo Ravelli, Sarah Ringold, Nicolino Ruperto, M. Suzanne Schrandt, Susan Shenoi, Natalie J. Shiff, Karine Toupin-April, Nikolay Tzaribachev, Pamela Weiss and Alessandro Consolaro
The Journal of Rheumatology August 2019, 46 (8) 1006-1013; DOI: https://doi.org/10.3899/jrheum.181088
Esi M. Morgan
From the Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio; Office of Research, Division of Rheumatology, Columbia University Medical Center, New York; Division of Rheumatology, University of Rochester, Golisano Children’s Hospital, Rochester, New York; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Thornhill Associates, Hermosa Beach, California; Division of Rheumatology, Children’s Mercy, Kansas City, Kansas City, Missouri; Division of Pediatric Rheumatology, Rutgers Robert Wood Johnson Medical School, Institute for Health, Health Care Policy and Aging Research, New Brunswick, New Jersey; University of Alabama at Birmingham, Birmingham, Alabama; Division of Rheumatology, Seattle Children’s Hospital, Seattle, Washington; Patient Engagement, Arthritis Foundation, Atlanta, Georgia; University of Florida, Shands Children’s Hospital, Gainesville, Florida; Division of Rheumatology, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania; USA; Royal Children’s Hospital; Murdoch Children’s Research Institute Melbourne, Melbourne; Consumer and Community Health Research Network, Crawley, Australia; Ottawa Hospital Research Institute; School of Epidemiology and Public Health, University of Ottawa; Department of Pediatrics and School of Rehabilitation Sciences, University of Ottawa; Children’s Hospital of Eastern Ontario Research Institute, Ottawa; Institute of Health Policy Management and Evaluation, University of Toronto; Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Sciences, Hospital for Sick Children, Toronto, Ontario, Canada; Institute for Research and Health Care (IRCCS) Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia; Università degli studi di Genova, Genoa; Rheumatology Division, Ospedale Pediatrico Bambino Gesù, Rome, Italy; Amsterdam Rheumatology and Immunology Center/Reade l Emma Children’s Hospital, Amsterdam Medical Center, Amsterdam, the Netherlands; Rheumatology, Respiratory, Gastroenterology and Immunology Office Scientific and Regulatory Management Department European Medicines Agency, London, UK; University of Nis, Faculty of Medicine, Department of Pediatric Rheumatology, Nis, Serbia; Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Esi M. Morgan
  • For correspondence: esi.morgan_dewitt{at}cchmc.org
Jane E. Munro
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Horonjeff
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ben Horgan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ben Horgan
Beverley Shea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Beverley Shea
Brian M. Feldman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Brian M. Feldman
Hayyah Clairman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clifton O. Bingham III
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Clifton O. Bingham III
Susan Thornhill
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vibeke Strand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vibeke Strand
Alessandra Alongi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alessandra Alongi
Silvia Magni-Manzoni
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Silvia Magni-Manzoni
Marion A.J. van Rossum
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marion A.J. van Rossum
Richard Vesely
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Richard Vesely
Jelena Vojinovic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jelena Vojinovic
Hermine I. Brunner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hermine I. Brunner
Julia G. Harris
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Julia G. Harris
Daniel B. Horton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Daniel B. Horton
Daniel J. Lovell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Daniel J. Lovell
Melissa Mannion
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Melissa Mannion
Homaira Rahimi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Homaira Rahimi
Angelo Ravelli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Angelo Ravelli
Sarah Ringold
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sarah Ringold
Nicolino Ruperto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nicolino Ruperto
M. Suzanne Schrandt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for M. Suzanne Schrandt
Susan Shenoi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Susan Shenoi
Natalie J. Shiff
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Natalie J. Shiff
Karine Toupin-April
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Karine Toupin-April
Nikolay Tzaribachev
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pamela Weiss
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pamela Weiss
Alessandro Consolaro
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alessandro Consolaro
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

Article Figures & Data

Figures

  • Tables
  • Initial OMERACT domain framework for juvenile idiopathic arthritis clinical trials and longitudinal observational studies. Note this figure does not show domains considered mandatory in specific circumstances and is not recommended for use (see Figure 2).
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Initial OMERACT domain framework for juvenile idiopathic arthritis clinical trials and longitudinal observational studies. Note this figure does not show domains considered mandatory in specific circumstances and is not recommended for use (see Figure 2).

  • OMERACT domain framework for juvenile idiopathic arthritis (JIA) studies including mandatory domains in specific circumstances. Recommended for use. *Illustrative examples (incomplete list): oligoarthritis: eye inflammation/uveitis; systemic JIA: fever, systemic rash, macrophage activation syndrome features; psoriatic arthritis: psoriasis; enthesitis-related arthritis: enthesitis, etc., to be determined.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    OMERACT domain framework for juvenile idiopathic arthritis (JIA) studies including mandatory domains in specific circumstances. Recommended for use. *Illustrative examples (incomplete list): oligoarthritis: eye inflammation/uveitis; systemic JIA: fever, systemic rash, macrophage activation syndrome features; psoriatic arthritis: psoriasis; enthesitis-related arthritis: enthesitis, etc., to be determined.

Tables

  • Figures
    • View popup
    Table 1.

    Online discussion board participants and main features when JIA is inactive by country.

    CountriesTeen, 15–18 YrsYoung Adults, 19–24 YrsParents, Younger ChildrenParents, Older Children
    United States11131010
    Italy11101010
    Australia3587
    Patient-reported Main Features when JIA is Inactive across Countries
    AustraliaItalyUSA
    No, or less pain (manageable)No painNo pain (less or tolerable pain)
    No, or less swellingNo swellingNo swelling
    Normal physical activityNo activity restrictionsCan participate in activities
    Positive mood (less irritability/anger, depression/sadness)Mood, no anxietyBetter mood (happier, less stress)
    No, or less stiffnessNo stiffnessLack of stiffness
    Better mobility (walk, run, exercise)No functional limitationsMobility (move, walk, run, exercise)
    More energy/less fatigueVitalityBetter energy/less fatigue
    No sleeplessnessBetter sleep
    No red-hot joints (inflammation)Minimal inflammation
    • JIA: juvenile idiopathic arthritis.

    • View popup
    Table 2.

    Delphi survey respondent characteristics. Values are n unless otherwise specified.

    Respondent CharacteristicsRound 1, n = 190, Response Rate 85%Round 2, n = 201, Response Rate 84%Round 3, n = 182, Response Rate 77%
    Patient/parent categories
      Patient161312
      Parent/caregiver557460
      Leader JIA association131211
    Other stakeholder categories*
      HCP948280
        Pediatric rheumatologist, subset of HCP847371
        > 10 yrs’ experience76%74%73%
      JIA researcher474139
      Clinical trials experience504842
      FDA/EMA465
    Patient/sample characteristics
      Patient age, yrs, mean353137
      Patient age at diagnosis, yrs, mean666
      Polyarticular (child)55%46%47%
      Oligoarticular (child)18%22%22%
      Systemic arthritis (child)13%16%12%
      Enthesitis-related arthritis (child)9%8%12%
      Psoriatic arthritis (child)4%8%8%
    • ↵* Categories are nonexclusive. HCP: healthcare provider; JIA: juvenile idiopathic arthritis; FDA: US Food and Drug Administration; EMA: European Medicines Agency.

    • View popup
    Table 3.

    Domain definitions used for Delphi Survey voting reference.

    DomainExample Items that May Be Included in this Domain
    Activity limitationEffect on physical function/physical disability, effect on activities of daily life
    Coping with illnessCoping with medication administration, effect on family, adherence to therapy
    Eye inflammationUveitis, iritis, related vision loss
    FatigueTiredness, lack of energy, lack of vitality
    Growth and maturationHeight, weight, Tanner stage (puberty), fertility
    Health care useCosts of care, frequency of medical visits
    Imaging signs of inflammationMRI, ultrasound, radiographs
    Effect on emotional function, mood or cognitionDepressive symptoms, anxiety, need for psychologic/psychiatric support, cognition, ability to think
    Effect on social relationshipsEffect on relationships with friends, family, etc.
    Inflammatory signs outside of joints and eyesFever, systemic rash, psoriasis, enthesitis, back pain, etc.
    Joint damagePermanent deformity, fixed contracture, erosions, etc.
    Joint inflammatory signsRedness, swelling, warmth, tenderness, “active joint,” limitation in joint ROM
    Laboratory signs of inflammationAcute-phase reactants (ESR, CRP, etc.)
    PainPain intensity, effect of pain, usage of (nonspecific) pain killers (yes/no)
    Patient’s perception of disease activityOverall well-being: “considering all the way your JIA affects you, how would you rate your overall well-being?”, patient’s global assessment, health-related quality of life
    Participation restrictionEffect on school/work, days absent from school, effect on social event attendance and leisure activities
    Personal factorsSelf-esteem, locus of control, motivation
    Physical activityExercise, sedentary behavior
    Physician’s perception of disease activityPGA, PGA for inflammation, PGA for damage, PGA for disease effect, PGA for severity
    Side effectsMedication adverse effects
    SleepQuality of sleep
    StiffnessMorning stiffness, gelling, joint stiffness
    • MRI: magnetic resonance imaging; ROM: range of motion; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; JIA: juvenile idiopathic arthritis; PGA: physician’s global assessment.

    • View popup
    Table 4.

    Results of Delphi round 3 and domain placement in OMERACT Onion Framework after consensus voting.

    VariablesPatients/ParentsOther StakeholdersAverage of Sums 5
    InnerMiddleSumInnerMiddleSum
    Mandatory domains (inner circle/core set)
      Pain1886777
      Joint inflammatory signs/active joints1508970
      Side effects/adverse events2635860
      Activity limitation/physical function376189479199896
      Patient’s perception of disease/overall well-being432568866259190
    Important but optional domains (middle circle)
      Joint damage71259641509193
      Laboratory signs of inflammation (acute-phase reactants)53379082169693
      Eye inflammation47479462369896
      Inflammatory signs outside joints/eyes464490663410095
      Physician’s perception of disease activity32528483149790
      Stiffness46489446449192
      Growth and maturation28548223648785
      Participation restriction30568624557882
      Imaging signs of inflammation25588425557981
      Physical activity (exercise)1673893626577
      Fatigue4252945545876
      Effect on emotional function, mood, cognition4247898455471
    Research agenda (outer circle)
      Coping with illness2061815495467
      Healthcare use2453774364058
      Sleep867750404057
      Effect on social relationships1356681323351
      Personal factors1456701303151
    • ↵1 Domains voted into inner circle with round 1 of Delphi.

    • ↵2 Side effects/adverse events is a mandatory domain for all clinical trials per OMERACT Handbook.

    • ↵3 Domain placement rules for Delphi round 3 based on percent votes for inner circle and middle circle: if average of inner circle votes for both stakeholder groups > 70% recommend inner circle. If sum of inner circle plus middle circle votes > 70% for both stakeholder groups (but average of inner circle votes alone is not > 70%), recommend middle circle. If sum of inner circle and middle circle votes > 70% for only 1 stakeholder group, but average > 70%, then consider middle circle. If sum of inner circle and middle circle votes > 70% for only 1 or none of the stakeholder groups, and average < 70%, then recommend outer circle.

    • ↵4 Inclusion of patient’s perception of disease/overall well-being in inner circle based on OMERACT workshop voting does not follow suggested domain placement rules. See text.

    • ↵5 “Average of sums” is average of inner circle plus middle circle votes for both stakeholder groups from Delphi round 3. The sums do not add to 100 because of exclusion of the votes for outer circle from presentation in the table. OMERACT: Outcome Measures in Rheumatology.

    • View popup
    APPENDIX 1.

    List of 27 items included in Round 1 of Delphi survey.

    Coping with administering medication
    Coping with long-term chronic disease
    Costs of care
    Eye manifestations of JIA
    Fatigue
    Growth and maturation
    Imaging of joints (magnetic resonance imaging, ultrasound, radiographs)
    Effect on ability to attend school or work
    Effect on ability to participate in normal life situations and roles
    Effect on ability to perform activities of daily living
    Effect on cognition
    Effect on emotional well-being
    Effect on independence/autonomy
    Effect on level of physical activity
    Effect on participation (leisure)
    Effect on physical appearance
    Effect on relationships
    Joint damage or deformity
    Joint stiffness
    Joint swelling/redness/warmth
    Laboratory tests of inflammation
    Medication side effects
    Occurrence of inflammatory signs outside of the joints (skin, rash, fever)
    Pain
    Patient’s subjective perception of his/her health
    Quality of sleep
    Restriction in joint range of motion.
    • JIA: juvenile idiopathic arthritis.

    • View popup
    APPENDIX 2.

    List of “write-in” items after Round 1 of Delphi survey.

    Adherence to therapy
    Back pain
    Comorbid conditions
    Enthesitis
    Fever
    Effect on family
    Effect on fertility
    Effect on self-esteem
    Locus of control
    Morning stiffness
    Motivation
    Number of medical appointments
    Physician global assessment
    Professional psychological help
    Psoriasis
    School days missed
    Use of complementary/alternative medications
    Use of pain medications
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 46, Issue 8
1 Aug 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop
Esi M. Morgan, Jane E. Munro, Jennifer Horonjeff, Ben Horgan, Beverley Shea, Brian M. Feldman, Hayyah Clairman, Clifton O. Bingham, Susan Thornhill, Vibeke Strand, Alessandra Alongi, Silvia Magni-Manzoni, Marion A.J. van Rossum, Richard Vesely, Jelena Vojinovic, Hermine I. Brunner, Julia G. Harris, Daniel B. Horton, Daniel J. Lovell, Melissa Mannion, Homaira Rahimi, Angelo Ravelli, Sarah Ringold, Nicolino Ruperto, M. Suzanne Schrandt, Susan Shenoi, Natalie J. Shiff, Karine Toupin-April, Nikolay Tzaribachev, Pamela Weiss, Alessandro Consolaro
The Journal of Rheumatology Aug 2019, 46 (8) 1006-1013; DOI: 10.3899/jrheum.181088

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop
Esi M. Morgan, Jane E. Munro, Jennifer Horonjeff, Ben Horgan, Beverley Shea, Brian M. Feldman, Hayyah Clairman, Clifton O. Bingham, Susan Thornhill, Vibeke Strand, Alessandra Alongi, Silvia Magni-Manzoni, Marion A.J. van Rossum, Richard Vesely, Jelena Vojinovic, Hermine I. Brunner, Julia G. Harris, Daniel B. Horton, Daniel J. Lovell, Melissa Mannion, Homaira Rahimi, Angelo Ravelli, Sarah Ringold, Nicolino Ruperto, M. Suzanne Schrandt, Susan Shenoi, Natalie J. Shiff, Karine Toupin-April, Nikolay Tzaribachev, Pamela Weiss, Alessandro Consolaro
The Journal of Rheumatology Aug 2019, 46 (8) 1006-1013; DOI: 10.3899/jrheum.181088
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS, RESULTS
    • DISCUSSION
    • Acknowledgment
    • APPENDIX 1
    • APPENDIX 2
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Keywords

OMERACT
JUVENILE IDIOPATHIC ARTHRITIS
OUTCOME ASSESSMENT
CLINICAL TRIALS
QUALITY OF LIFE

Related Articles

Cited By...

More in this TOC Section

  • Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology
  • PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials
  • Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology
Show more Workshops and Special Sessions

Similar Articles

Keywords

  • OMERACT
  • juvenile idiopathic arthritis
  • outcome assessment
  • clinical trials
  • quality of life

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire